Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.52 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PPME1 | Q9Y570 | 6/20 | 0.38 |
| ▸ | APEH | P13798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464163 | 0.75 | TRIM24 (0.42) | TRIM24TRIM33ATMALDH1A1GAA | |
| SCHEMBL1616366 | 0.75 | PPME1 (0.60) | TRIM24TRIM33ATMALDH1A1PPME1 | |
| SCHEMBL2457308 | 0.74 | RAPGEF4 (0.58) | TRIM24TRIM33ALDH1A1GAAPPME1 | |
| SCHEMBL30895883 | 0.74 | HCAR2 (0.40) | ATMPPME1APEHKMT2A | |
| SCHEMBL30895905 | 0.74 | HCAR2 (0.40) | ATMPPME1APEHKMT2A | |
| SCHEMBL29221130 | 0.73 | RAPGEF4 (0.59) | TRIM24TRIM33ATMALDH1A1GAA | |
| SCHEMBL5247297 | 0.72 | RAPGEF4 (0.60) | TRIM24TRIM33ALDH1A1PPME1APEH | |
| SCHEMBL15155241 | 0.71 | HTR6 (0.39) | ALDH1A1PPME1APEHHTR6 | |
| SCHEMBL3964676 | 0.71 | PPME1 (0.45) | TRIM24TRIM33PPME1APEHHTR6 | |
| SCHEMBL3964674 | 0.71 | PPME1 (0.58) | ALDH1A1PPME1APEHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2021-07-08 | — | — | US | disclosed |
| CN-106866658-B | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | 沃纳利斯(R&D)有限公司 | 2021-04-27 | — | — | CN | disclosed |
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | VERNALIS (R&D) LIMITED (GB) | 2021-01-12 | — | — | US | disclosed |
| CN-111484493-A | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | 沃纳利斯(R&D)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20180362526-A1 | 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| US-10000481-B2 | 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors | VERNALIS (R&D) LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| EP-2809670-B1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| US-20150011533-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2015-01-08 | — | — | US | disclosed |
| EP-2809670-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Vernalis (R&D) Limited (GB) | 2014-12-10 | — | — | EP | disclosed |
| CN-104203948-A | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | VERNALIS R&D LTD | 2014-12-10 | — | — | CN | disclosed |
| US-20080275042-A1 | 4-Phenyl-5-Oxo-1,4,5,6,7,8-Hexahydroquinoline Derivatives for the Treatment of Infertility | N.V. ORGANON (NL) | 2008-11-06 | — | — | US | disclosed |
| EP-1881830-B1 | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY | ORGANON NV (NL) | 2008-10-08 | — | — | EP | disclosed |
| CN-101212973-A | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility | ORGANON NV (NL) | 2008-07-02 | — | — | CN | disclosed |
| EP-1881830-A1 | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY | N.V. Organon (NL) | 2008-01-30 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| WO-2006117368-A1 | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY | N.V. ORGANON (NL) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275042-A1 | 4-Phenyl-5-Oxo-1,4,5,6,7,8-Hexahydroquinoline Derivatives for the Treatment of Infertility | CATSPER1, ABCB11, ACR | TRIM24 3988/4885TRIM33 3373/4885ATM 2568/4885 |
| US-10000481-B2 | 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors | MAP4K2, MAP3K1, MAP3K19 | TRIM24 2352/4885TRIM33 2545/4885ATM 420/4885 |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | TRIM24 4706/4885TRIM33 4220/4885ATM 4357/4885 |
| US-20180362526-A1 | 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | TRIM24 2352/4885TRIM33 2545/4885ATM 420/4885 |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | TRIM24 2352/4885TRIM33 2545/4885ATM 420/4885 |
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | MAP4K2, MAP3K1, MAP3K19 | TRIM24 2352/4885TRIM33 2545/4885ATM 420/4885 |
| US-20150011533-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | TRIM24 2352/4885TRIM33 2545/4885ATM 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.